The project aims to improve patient safety, reduce barriers to the implementation of current guideline recommendations, reduce workload in clinics, increase efficiency in work processes and close gaps in care.

开始日期2024-06-03

申办/合作机构

Barmer

[+1]

NCT05818449 / Active, not recruitingN/AIIT

Improvement of Personalized Cancer Care for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Through Digital Connection of Specialized Cancer Centers, Community Hospitals, Private Practices and Patients (DigiNet)

The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promotes the transfer of the latest scientific knowledge into standard care. The DigiNet project is based on the established precision medicine program, the National Network Genomic Medicine Lung Cancer (nNGM) in Germany, whereby every patient receives molecular diagnostics and personalized therapy information after the initial diagnosis. Within the framework of the DigiNet project, specialized academic centers will be digitally connected with practitioners via a shared project database. Furthermore, a committee of experts will monitor the course of treatment and will advise the practitioners in case of critical conditions. Additionally, patient-reported outcomes will be incorporated into the treatment.

开始日期2022-06-01

申办/合作机构

Barmer

[+8]

NCT04977362 / Active, not recruitingN/AIIT

Interdisciplinary and Cross-sectoral Perioperative Care Model in the Cardiac Surgery: Implementation in the Setting of Minimally-invasive Heart Valve Surgery (INCREASE)

Valvular heart diseases are among the most common cardiac pathologies in adult patients in Germany. Currently, the process of care before, during and after heart valve surgery does not follow a standardized and interdisciplinary optimal approach. An approach already established in other surgical disciplines is the Enhanced Recovery After Surgery (ERAS) protocol, which aims at optimizing the recovery process of patients. Within the INCREASE study, a care process inspired by the ERAS protocol will be established at the University Heart and Vascular Center (UHZ) of the University Medical Center Hamburg-Eppendorf (UKE) and the University Medical Center Augsburg (UKA). Executing the study at two facilities in different regions in Germany will help to demonstrate transferability of the process of care. The effectiveness of this process compared to the current treatment approach will be investigated in a randomized controlled trial. A total of 186 patients will be allocated by chance either to the intervention group (ERAS protocol) or the control group (treatment as usual). Patients in the intervention group will receive an optimized interdisciplinary care protocol including medical, nursing, physiotherapeutical and psychotherapeutical interventions. Measurements of effectiveness are the number of hospitalized days (due to cardiac causes) within one year and the physical condition of the patient as measured by the 6-minute walk test (6MWT) on the day of discharge.

开始日期2021-07-01

申办/合作机构

Universitätsklinikum Hamburg-Eppendorf

[+2]

100 项与 Barmer 相关的临床结果

登录后查看更多信息

0 项与 Barmer 相关的专利（医药）

登录后查看更多信息

项与 Barmer 相关的文献（医药）

2013-06-01·European Archives of Psychiatry and Clinical Neuroscience2区 · 医学

High rehospitalization rate in alcohol-induced psychotic disorder

2区 · 医学

Article

作者: Marcus Cleves ; Michael Soyka ; Bernd Helten ; Peggy Schmidt

Little is known about the prevalence and in particular the outcome of alcohol-induced psychotic disorder (AIPD). Data from hospital statistics of the BARMER GEK, one of the major health insurance companies in Germany, show a low overall prevalence of AIPD. An analysis of readmission rates for patients hospitalized for AIPD in 2005 (N = 462) and 2006 (N = 404) for the period up to 2010 revealed very high readmission rates. Only a minority of patients were without relapse [144 (31.2%) of the 2005 sample; 152 (37.6%) of the 2006 sample]. Thus, AIPD appears to be a rare complication of the alcohol use disorder but to have an extremely high rehospitalization rate, probably indicating a more chronic course and worse prognosis than previously thought. More follow-up studies are needed to elucidate this syndrome.

Use of an electronic medication management support system in patients with polypharmacy in general practice: study protocol of a quantitative process evaluation of the AdAM trial

作者: Muth, Christiane ; Akker, Marjan van den ; Chapidi, Kiran ; Kellermann-Mühlhoff, Petra ; Brünn, Robin ; Köberlein-Neu, Juliane ; Piotrowski, Alexandra ; Timmesfeld, Nina ; Lemke, Dorothea ; Greiner, Wolfgang ; Söling, Sara

AbstractBackground: Much research is currently devoted to polypharmacy, but interventional studies often fail to significantly improve patient-relevant outcomes or just measure surrogate parameters. Interventions and their settings are often complex, and a wide range of factors affect results. The aim of the AdAM study is to reduce hospitalization and death by requiring general practitioners (GPs) to use a computerized decision-support system (CDSS). The study will undergo a process evaluation to identify relevant factors for successful implementation and to assess whether the intervention was implemented as intended.Research questions: We will assess implementation (reach, fidelity, dose, tailoring) by asking the following questions: (1) Who took part in the intervention, i.e., the proportion of GPs that used the CDSS, and the proportion of patients that were enrolled by them? Information on the characteristics of GPs and patients will also be collected. (2) How many and what type of medication alerts were handled by the GPs? (3) Was the intervention implemented as intended? (4) On what days did GPs use the intervention tool? We will conduct subgroup analyses to all questions, including time effects to account for software improvements over time.Methods: The process evaluation is part of a stepped wedge cluster-randomized controlled trial. Characteristics of practices, GPs and patients using the CDSS will be compared with the non-participating population. CDSS log data will be analyzed to evaluate how the number of medication alerts changed between baseline and two months later and identify the kind of medication alerts that are given highest priority. The comparison of enrolled patients on weekdays vs weekends will shed light on whether GPs use the CDSS in the absence or presence of patients. All outcomes will be presented using descriptive statistics, and significance tests will be used to identify any associations between them.Discussion: This study protocol is the basis for conducting the analyses of the log data-based process evaluation. By providing insight into the way GPs conduct medication reviews, the evaluation will provide a context to the trial results and support their interpretation. The evaluation relies on the proper documentation of what the CDSS was used for, which may limit its explanatory power.Trial registration: ClinicalTrials.gov, NCT03430336. Registered on February 6, 2018. https://clinicaltrials.gov/ct2/show/NCT03430336

B&G Bewegungstherapie und Gesundheitssport

Osteoporose-betroffene Frauen im Rehabilitationssport und Funktionstraining – Eine empirische Analyse von Unterschieden und Gemeinsamkeiten

作者: Bühne, D ; Meierjürgen, R ; Kleinfeld, A ; Freikamp, T ; Schüle, K ; Begerow, B

项与 Barmer 相关的新闻（医药）

2024-02-14

·FierceBiotech

Earlybird gets the €173M worm, building nest egg for European healthcare companies

The healthcare-focused Earlybird VC fund will support companies across digital health, diagnostics, medical devices, R&D tools and biopharma areas. Earlybird Health is taking flight with 173 million euros ($186 million), a nest egg that will go toward European healthcare companies ranging from early development to late-stage tech nearing regulatory approval and commercialization. The Earlybird Venture Capital fund will support companies across digital health, diagnostics, medical devices, R&D tools and biopharma sectors, according to a Feb. 14 release. The tech-agnostic VC will use its AI tool, dubbed Earlybird Eagle Eye, to scout out new startups and gather information. The tech is designed to boost companies’ deal flow by providing market intelligence through competitor analyses and trend reports. Several institutional investors in Europe participated in the fund, including the British Patient Capital, a commercial affiliate of the government-owned British Business Bank, and BARMER, a leading public health insurer in Germany. Biotechs currently under Earlybird’s wing include Ariceum Therapeutics, Grey Wolf Therapeutics, ImCheck Therapeutics, Oculis and Priothera.

2024-02-14

·Endpoints

European investor Earlybird Health closes $185M fund to back 12 to 15 companies

Germany-based investor Earlybird Health has closed its second healthcare-focused fund and has already deployed some of it in biopharma and medtech companies, with one exit in the books and another in sight, partner Florent Gros told Endpoints News . Earlybird’s €173 million (about $185 million) second fund comes on the heels of multiple other VC fund hauls disclosed in recent weeks at the likes of The Column Group , Scion Life Sciences and others. It is significantly larger than the firm’s first healthcare-dedicated fund from 2016 that closed at €85 million. British Patient Capital and BARMER, a public health insurer in Germany, were some of the investors in the new fund.

2024-02-14

·BioSpace

European-Based VC Earlybird Health Closes $186M Fund

Pictured: European flags flap in the wind outside EU headquarters in Brussels, Belgium on July 21, 2022/iStock, Alexandros Michailidis The German-based venture capital fund Earlybird Health has closed its latest healthcare fund totaling €173 million ($185.4 million), the group announced Thursday. According to Earlybird Health, this latest fund is “significantly” larger than its previous fund and will be put towards companies in Europe who are in the early stages of development to help advance technologies that are close to getting regulatory approval and eventual commercialization. The fund is looking to put its money into companies that are in the biopharma sector as well as diagnostics, digital health, medical devices and R&D tools. Earlybird noted that the fund is backed “major institutional investors” in Europe including health insurers, strategic investors as well as public and private investors. The investors include BARMER, a German public health insurer. “We are proud to pave the way for health insurers to invest in venture capital through our ongoing support for Earlybird Health. This reflects our commitment to fostering innovation within the German and European healthcare ecosystem. We are confident these efforts will yield positive outcomes for patients worldwide,” BARMER CEO Christoph Straub said in a statement. Earlybird said that the company uses its own AI-based technology, known as Eagle Eye, for its deal sourcing and plans for it to be a cornerstone of its future financing rounds. “Eagle Eye will soon be the driver of a more effective, efficient, and inclusive deal sourcing and due diligence process for our investment teams. Earlybird Health is proud to set the standard for dynamic and informed deal flow in the European healthcare sector,” Christoph Massner, principal at Earlybird Health, said in a statement. Earlybird has not been the only fund that has been raising capital to start out 2024. In January, Goldman Sachs Asset Management closed its first life sciences fund, called West Street Life Sciences I, securing $650 million for its arsenal. Earlier this month, Scion Life Sciences launched an oversubscribed fund of $310 million looking to invest in the life sciences sector. The fund is headed up by three industry veterans including Samuel Hall, former partner at Apple Tree Partners, Aaron Kantoff a former venture partner at Medicxi and Tadd Wessel, a managing partner at private healthcare investment firm Petrichor. Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

100 项与 Barmer 相关的药物交易

登录后查看更多信息

100 项与 Barmer 相关的转化医学

登录后查看更多信息